Browse By

Duncker Streett & Co. Inc. Decreases Position in Zimmer Biomet Holdings, Inc. (ZBH)

Zimmer Biomet Holdings logoDuncker Streett & Co. Inc. reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,064 shares of the medical equipment provider’s stock after selling 187 shares during the period. Duncker Streett & Co. Inc.’s holdings in Zimmer Biomet Holdings were worth $650,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in ZBH. Parkside Financial Bank & Trust boosted its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after buying an additional 199 shares during the last quarter. IHT Wealth Management LLC boosted its stake in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 256 shares during the last quarter. Sandy Spring Bank boosted its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares during the last quarter. Finally, Penserra Capital Management LLC boosted its stake in shares of Zimmer Biomet Holdings by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,288 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 112 shares during the last quarter. 83.62% of the stock is owned by hedge funds and other institutional investors.

Get Zimmer Biomet Holdings Inc. alerts:

Zimmer Biomet Holdings, Inc. (ZBH) traded down 1.89% during trading on Wednesday, hitting $112.86. The stock had a trading volume of 1,852,423 shares. Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.49. The firm has a market cap of $22.78 billion, a price-to-earnings ratio of 32.14 and a beta of 1.20. The firm’s 50 day moving average is $127.65 and its 200 day moving average is $121.39.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. The company had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period last year, the company earned $2.02 EPS. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s payout ratio is presently 27.59%.

COPYRIGHT VIOLATION WARNING: “Duncker Streett & Co. Inc. Decreases Position in Zimmer Biomet Holdings, Inc. (ZBH)” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.com-unik.info/2017/08/09/zimmer-biomet-holdings-inc-zbh-position-reduced-by-duncker-streett-co-inc-updated.html.

A number of equities research analysts recently issued reports on ZBH shares. BMO Capital Markets reissued a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Canaccord Genuity restated a “buy” rating on shares of Zimmer Biomet Holdings in a report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 price objective on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Friday, April 28th. Jefferies Group LLC restated a “buy” rating and issued a $148.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, June 30th. Finally, Guggenheim upgraded shares of Zimmer Biomet Holdings from a “neutral” rating to a “buy” rating and set a $157.00 price objective on the stock in a report on Wednesday, July 12th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $137.76.

In related news, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

What are top analysts saying about Zimmer Biomet Holdings Inc.? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.

Leave a Reply

Your email address will not be published. Required fields are marked *